Document is current
Any future updates will be listed below
-
Authors
Wang, Guochang
Li, Linlin
Wang, Jiarou
Zang, Jie
Chen, Jingci
Xiao, Yu
Fan, Xinrong
Zhu, Lin
Kung, Hank F.
Zhu, Zhaohui
-
Funding
Funding for this research was provided by:
the Fundamental Research Funds for the Central Universities (3332022110)
the National High Level Hospital Clinical Research Funding (2022-PUMCH-C-002)
Chinese Academy of Medical Science Innovation Fund for Medical Sciences (2022-I2M-C&T-A-008, 2022-I2M-2-002, 2021-I2M-1-016)
Beijing Natural Science Foundation (M22035)
the National Natural Science Foundation of China (82272046, 81871392)
- License Information
-
More Information
Article History
Received: 27 October 2022
Accepted: 24 December 2022
First Online: 5 January 2023
Declarations
:
: Ethical approval was obtained from the Institute Review Board of Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (no. ZS-2532), and this study was conducted in accordance with the principles of the Declaration of Helsinki.
: Informed consent was obtained from all participants included in the study.
: Hank F. Kung is the founder of Five Eleven Pharma, which holds the patent rights for [<sup>68</sup>Ga]Ga-P16-093 and related technology. Other authors have no conflicts of interest or relevant financial activities to disclose.
